Showing 1 to 1 of 1 results
abcnews.go.com
🌐 85% Global Worthiness


Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial
Eli Lilly's Phase 3 trial of the oral GLP-1 drug orforglipron showed an average weight loss of 27.3 pounds (12% body weight) in over 3,100 overweight or obese adults over 72 weeks, with cardiovascular benefits and side effects similar to injectable GLP-1s; the company plans to seek regulatory approv...
Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial
Eli Lilly's Phase 3 trial of the oral GLP-1 drug orforglipron showed an average weight loss of 27.3 pounds (12% body weight) in over 3,100 overweight or obese adults over 72 weeks, with cardiovascular benefits and side effects similar to injectable GLP-1s; the company plans to seek regulatory approv...
Progress
44% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results